

**RENOUNCEABLE NON-UNDERWRITTEN RIGHTS ISSUE
– ISSUE AND LISTING AND QUOTATION OF THE RIGHTS SHARES**

1. INTRODUCTION

The board of directors (the “**Board**”) of Biolidics Limited (the “**Company**”) refers to the Company’s announcements dated 29 September 2022, 26 October 2022, 31 October 2022, 8 November 2022 and 30 November 2022 (“**Previous Announcements**”) and the offer information statement dated 8 November 2022 (“**Offer Information Statement**”) in relation to the Rights Issue.

Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Offer Information Statement.

2. ALLOTMENT AND ISSUANCE OF THE RIGHTS SHARES

Further to the Previous Announcements, the Board is pleased to announce that pursuant to the Rights Issue, an aggregate of 227,916,205 Rights Shares have been allotted and issued by the Company on 2 December 2022. The Company expects the Rights Shares to be credited into the relevant securities account on or about 5 December 2022.

Following the allotment and issuance of the Rights Shares, the number of issued and paid-up Shares (excluding treasury shares and subsidiary holdings) has increased from 265,451,700 Shares to 493,367,905 Shares.

The Rights Shares, when allotted and issued, will rank *pari passu* in all respects with the then existing Shares, save for any dividends, rights, allotments or other distributions, the record date for which falls before the date of issue of the Rights Shares.

3. LISTING AND QUOTATION OF THE RIGHTS SHARES

The Rights Shares will be listed and quoted on Catalist with effect from 9.00 a.m. on 5 December 2022 and the trading of the Rights Shares will commence with effect from 9.00 a.m. on the same day.

BY ORDER OF THE BOARD

Song Tang Yih
Executive Director and Chief Executive Officer
2 December 2022

This announcement has been prepared by the Company and has been reviewed by the Sponsor for compliance with Rules 226(2)(b) and 753(2) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Lim Hoon Khat, Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.